Showing 15 posts of 20 posts found.


Celltrion launches Humira biosimilar in US

July 7, 2023
Medical Communications Chronic Diseases, Humira, Yuflyma, arthritis, celltrion

South Korean biopharmaceutical company Celltrion has announced that its US branch – Celltrion USA – has launched a Humira (adalimumab) …


Experimental COVID antibody treatment successful in trials

June 14, 2021
Sales and Marketing COVID-19, antibody therapy, celltrion, phase III

Celltrion has announced positive top-line data for its experimental antibody COVID-19 treatment, with Phase III trials finding it safe and …

Celltrion’s COVID-19 treatment shows promise against South African variant

April 30, 2021
Medical Communications COVID-19, celltrion, covid 19 news, covid-19 news, covid-19 treatment, pharma, pharma news

Celltrion’s regdanvimab treatment for COVID-19 has shown itself to be effective against the South African variant of the virus, according …


Celltrion’s inflammatory disease drug Yuflyma gets EU approval for 13 indications

February 16, 2021
Manufacturing and Production EC, celltrion

The European Commission (EC) has granted marketing authorisation for Celltrion’s Yuflyma, an adalimumab biosimilar, across all thirteen intended indications for …


South Korea approves Celltrion’s COVID-19 treatment Regdanvimab for emergency use

February 8, 2021
Sales and Marketing COVID-19, celltrion

The South Korean Ministry of Food and Drug Safety (MFDS) has granted a conditional marketing authorisation (CMA) for the emergency …


Celltrion announces positive top-line results from COVID-19 treatment trial

January 14, 2021
COVID-19, celltrion

Celltrion Group has announced that top-line results from its global Phase II/III clinical trial of CT-P59, an anti-COVID-19 monoclonal antibody …


Celltrion’s Humira biosimilar is comparable in treating rheumatoid arthritis

November 4, 2020
Research and Development Humira, biosimilar, celltrion, rheumatoid arthritis

Celltrion has revealed new Phase 3 data demonstrating that its high concentration (100mg/mL) and citrate-free biosimilar CT-P17 proved comparable to …


Celltrion’s infliximab biosimilar Remsima secures European approval in five indications

July 27, 2020
Manufacturing and Production, Sales and Marketing celltrion, infliximab, pharma, remsima

The subcutaneous (SC) formulation of Remsima, Celltrion’s biosimilar version of infliximab, has secured approval from the European Commission covering five …


Takeda jettisons non-core portfolio in Asia Pacific to Celltrion for a potential $278 million

June 12, 2020
Medical Communications, Sales and Marketing Takeda, celltrion, pharma, sale

Takeda continues its mission to reduce its debt in the wake of its $49 billion acquisition of Shire in January …


FDA greenlights Celltrion HIV drug manufacturing facility in South Korea

March 16, 2020
Manufacturing and Production, Sales and Marketing FDA, celltrion, coronavirus, pharma

South Korean biopharma firm Celltrion has revealed that one of its key manufacturing facilities has been given the all-clear by …


Europe approves first subcutaneous version of biosimilar infliximab

November 26, 2019
Manufacturing and Production, Sales and Marketing arthritis, biosimilars, celltrion, infliximab, pharma

The European Commission has chosen to authorise Celltrion Healthcare’s Remsima SC, a biosimilar of infliximab and the first subcutaneous formulation …


Celltrion’s subcutaneous infliximab biosimilar secures CHMP recommendation

September 24, 2019
Manufacturing and Production, Sales and Marketing EMA, EU, Europe, biosimilar, celltrion, infliximab, pharma

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has given its recommendation to Celltrion’s CT-P13 SC, the subcutaneous …


Top Ten most popular articles on Pharmafile.com this week!

December 21, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Eisai, Eli Lilly, Novartis, Teva, Tilray, brexit, celltrion, pharma, top 10

Deals dominated this week as GSK and Pfizer announced that they would combine their consumer healthcare units in a collaboration …

Celltrion and Teva’s Herceptin biosimilar secures FDA approval in breast cancer

December 18, 2018
Manufacturing and Production, Sales and Marketing Herceptin, Herzuma, Teva, celltrion, pharma

Israeli and South Korean-based drug makers Teva and Celltrion are set to move in on the market share occupied by …

FDA approves first Rituxan biosimilar courtesy of Teva and Celltrion

November 29, 2018
Sales and Marketing FDA, Genentech, Rituxan, Roche, Teva, Truxima, biosimilars, celltrion

The FDA has announced the first US approval of a biosimilar version of Genentech’s Rituxan (rituximab), awarding marketing approval to …

Latest content